科瑞斯塔生物科技
KRYS
316.58
-13.42
-4.07%
科瑞斯塔生物科技
US · KRYS
#1515 按市值排名
上市于 2017
316.58
-13.42
-4.07%
实时 - 追踪5344个代码 - 心跳于57秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量增加了3家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 101.94% -0.04pp
- 机构数量
- 508 +3
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund76.34%
Hedge Fund17.23%
Individual/Insider9.94%
Public Company2.63%
VC/PE Fund2.15%
Private Company1.14%
Government Pension Fund1.06%
Sovereign Wealth Fund0.89%
Insurance Company0.26%
主要股东 截至 2026-06-30
FMR
14.93% · 4.42M 股
BlackRock
14.13% · 4.18M 股
Avoro Capital Advisors LLC
9.76% · 2.89M 股
Vanguard Portfolio Management, LLC
5.32% · 1.57M 股
Suma Krishnan
4.88% · 1.44M 股
Vanguard Capital Management, LLC
4.83% · 1.43M 股
Krish Krishnan
4.82% · 1.43M 股
State Street Global Advisors
4.56% · 1.35M 股
Soleus Capital Management, L.P.
3.17% · 939.25K 股
Capital Research
2.63% · 777.84K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 19次买入 · 25次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Suma Krishnan | Founder, COO, President of R&D and Director | 4.88% |
| Krish Krishnan | Chairperson & CEO | 4.82% |
| Dino Rossi | Independent Director | 0.17% |
| Kathryn Romano | Chief Accounting Officer | 0.08% |
| Laurent Goux | Senior VP & GM of Europe | 0.00% |
| Daniel Janney | Lead Independent Director | -- |
| Julian Gangolli | Independent Director | -- |
| E. Sutherland | Independent Director | -- |
| Alta Bioequities | -- | -- |
| Christopher Mason | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-13 | Daniel Janney | Lead Independent Director | Other Derivative Acquisition | +471 | -- |
| 2026-09-13 | Daniel Janney | Lead Independent Director | Other Derivative Acquisition | +1,187 | $340.03 |
| 2026-09-13 | Dino Rossi | Independent Director | Other Derivative Acquisition | +471 | -- |
| 2026-09-13 | Dino Rossi | Independent Director | Other Derivative Acquisition | +1,187 | $340.03 |
| 2026-09-13 | Julian Gangolli | Independent Director | Other Derivative Acquisition | +471 | -- |
| 2026-09-13 | Julian Gangolli | Independent Director | Other Derivative Acquisition | +1,187 | $340.03 |
| 2026-09-13 | E. Sutherland | Independent Director | Other Derivative Acquisition | +471 | -- |
| 2026-09-13 | E. Sutherland | Independent Director | Other Derivative Acquisition | +1,187 | $340.03 |
| 2026-09-13 | Christopher Mason | Independent Director | Other Derivative Acquisition | +471 | -- |
| 2026-09-13 | Christopher Mason | Independent Director | Other Derivative Acquisition | +1,187 | $340.03 |
| 2026-09-13 | Catherine Mazzacco | Independent Director | Other Derivative Acquisition | +471 | -- |
| 2026-09-13 | Catherine Mazzacco | Independent Director | Other Derivative Acquisition | +1,187 | $340.03 |
| 2026-09-03 | Krish Krishnan | Chairperson & CEO | Automatic Disposition | -520 | $354.54 |
| 2026-09-03 | Krish Krishnan | Chairperson & CEO | Open Market Disposition | -24,480 | $355.57–366.56 |
| 2026-09-03 | Suma Krishnan | Founder, COO, President of R&D and Director | Automatic Disposition | -520 | $354.54 |
| 2026-09-03 | Suma Krishnan | Founder, COO, President of R&D and Director | Open Market Disposition | -24,480 | $355.57–366.56 |
| 2026-08-13 | Dino Rossi | Independent Director | Other Disposition | -3,691 | -- |
| 2026-08-13 | Dino Rossi | Independent Director | Open Market Disposition | -25,000 | $325.60–333.23 |
| 2026-06-24 | John Thomas | General Counsel | Derivative Exercise and Sale | -1,000 | $179.25–347.27 |
| 2026-06-03 | Krish Krishnan | Chairperson & CEO | Automatic Disposition | -320 | $300.75 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
科瑞斯塔生物科技 讨论区 0 条评论